# Linping Gu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/linping-gu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 212 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 5 |
| i10-index | 4 |
| Last Known Institution | Shanghai Jiao Tong University |
| OpenAlex ID | https://openalex.org/A5100971912 |
| Works | 15 |

## Researcher papers

- [Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients](https://scholariq.org/papers/homologous-recombination-deficiency-hrd-can-predict-the-therapeutic-outcomes-of/)
- [Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma](https://scholariq.org/papers/clinical-analysis-of-95-cases-of-pulmonary-sarcomatoid-carcinoma/)
- [Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors](https://scholariq.org/papers/durable-clinical-response-of-lung-adenocarcinoma-harboring-egfr-19del-t790m-in/)
- [No significant association between the XRCC3 Thr241Met polymorphism and lung cancer risk: a meta-analysis](https://scholariq.org/papers/no-significant-association-between-the-xrcc3-thr241met-polymorphism-and-lung/)
- [An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis](https://scholariq.org/papers/an-open-observational-three-arm-clinical-study-of-2-3-cycles-of-treatment-as/)
- [Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer](https://scholariq.org/papers/real-world-outcomes-of-immunotherapy-based-neoadjuvant-therapy-in-resectable-non/)
- [Identification of a 15 DNA Damage Repair-Related Gene Signature as aPrognostic Predictor for Lung Adenocarcinoma](https://scholariq.org/papers/identification-of-a-15-dna-damage-repair-related-gene-signature-as-aprognostic/)
- [\[Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer\].](https://scholariq.org/papers/comparison-of-the-efficacy-of-nedaplatin-combined-with-docetaxel-and-docetaxel/)
- [An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer](https://scholariq.org/papers/an-open-observational-clinical-study-of-neoadjuvant-therapy-in-resectable-stage/)
- [Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone](https://scholariq.org/papers/non-significant-efficacy-of-icotinib-plus-pleurodesis-in-epidermal-growth-factor/)
- [Clinical and genetic characteristics of EGFR-mutant lung adenocarcinoma transformed SCLC.](https://scholariq.org/papers/clinical-and-genetic-characteristics-of-egfr-mutant-lung-adenocarcinoma/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [DNA Repair Mechanisms](https://scholariq.org/topics/dna-repair-mechanisms/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Shanghai Jiao Tong University](https://scholariq.org/institutions/shanghai-jiao-tong-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.